ERBB2 and aneurysmal bone cyst: In the 624 patients diagnosed with metachronous metastases (excluding de novo ABC), prior HER2-targeted therapy in the adjuvant setting was associated with a threefold higher risk of discordance (versus no HER2-targeted: OR = 3.60; 95% CI: 2.05–6.35) (Table 2).